Breast Cancer Research

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors

Cancer Treatment Reviews

Risk of QTc prolongation, and major cardiovascular adverse events associated with CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer - A systematic review and meta-analysis

Annals of Oncology

Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial

Lancet Regional Health

Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy

Cancers

HER2-low and HER2-ultralow metastatic breast cancer and trastuzumab deruxtecan: Common clinical questions and answers

Biomedicines

Cryotherapy as a surgical de-escalation strategy in breast cancer: Techniques, complications, and oncological outcomes

eLife

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

Annals of Oncology

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: Final overall survival analysis of the phase 3 TROPION-Breast01 study

Anti-Cancer Research

Radiological complete response as a prognostic marker in HR-positive metastatic breast cancer treated with CDK4/6 inhibitors: Implications for treatment de-escalation

Anti-Cancer Drugs

Efficacy and safety of fulvestrant combined with abemaciclib in patients with hormone receptor-positive advanced breast cancer